Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07368322

Comparative Research of Y-Incision vs. Standard Techniques for Aortic Root EnLargement

Abstract Background: Aortic valve replacement (AVR) is crucial for patients with severe aortic valve disease. However, managing those with a small aortic annulus (SAA, i.e., annulus diameter < 22 mm) is challenging because implanting a small prosthesis can result in patient-prosthesis mismatch (PPM), suboptimal hemodynamic outcomes, and reduced long-term survival. Traditional surgical techniques for aortic root enlargement (ARE), such as the Nicks and Manougian procedures, have significant limitations, typically allowing enlargement of only one to two prosthesis sizes and involving complex reconstructive procedures. The novel "Y incision" technique by Bo Yang offers a promising alternative, allowing implantation of valves up to five sizes larger than the native annulus, but it lacks comprehensive comparative data on its safety, efficacy, and functional outcomes.

Aim: This study aims to compare the safety outcomes, hemodynamic performance, and functional capacity of the "Y incision" technique versus standard surgical enlargement techniques in patients with a small aortic annulus undergoing AVR, with particular emphasis on objective functional assessment using cardiopulmonary exercise testing (CPET).

Methods: This prospective, randomized, controlled superiority trial will enroll patients with aortic valve disease and a small aortic annulus where conventional AVR is expected to result in moderate or severe PPM. Patients will be randomized 1:1 to either the standard surgical technique group or the "Y incision" technique group. Based on preliminary results and power calculations using the Win Ratio methodology, the sample size is set at 90 patients (45 in each group) to account for potential dropouts.

Primary Endpoint: Hierarchical composite endpoint analyzed using Win Ratio methodology, including (in order of priority): all-cause mortality, stroke, myocardial infarction, total hospitalization rate, moderate or severe PPM, exercise-induced valve dysfunction, and functional improvement at specified time points through 12 months.

Secondary Endpoints: Safety outcomes including intraoperative and 30-day complications, long-term anatomical complications, hemodynamic parameters assessed by echocardiography, functional outcomes measured by 6-minute walk distance and CPET (including peak VO₂), quality of life assessed using KCCQ questionnaire, and prosthetic valve-related outcomes at 3, 6, and 12 months post-surgery.

Conclusion: By providing robust, randomized controlled data with objective functional capacity assessment, this study aims to fill current gaps in knowledge regarding the long-term outcomes, safety profile, and functional benefits of the "Y incision" technique compared to standard surgical methods, potentially establishing evidence-based guidance for managing patients with a small aortic annulus undergoing AVR.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-80 years.
  • Patients must have signed and dated an ICF in accordance with regulatory and institutional guidelines before any protocol-related procedures and must be willing and able to comply with scheduled visits.
  • Diagnosed with aortic valve disease requiring aortic valve replacement.
  • Patients with small aortic annulus relative to body size where conventional AVR result in moderate or severe PPM (defined as cases where the largest prosthesis that can be implanted in the native annulus would provide a predicted iEOA ≤0.85 cm²/m² for BMI <30, or ≤0.70 cm²/m² for BMI ≥30), based on manufacturer specifications and patient BSA).
  • Suitable candidates for surgery as determined by the heart team.

Exclusion criteria

  • Patients for whom conventional AVR without root enlargement is not expected to result in patient-prosthesis mismatch.
  • Prior cardiac surgery.
  • Severe concomitant valvular disease requiring additional procedures.
  • Active endocarditis.
  • Severe chronic lung disease
  • Pre-existing lower limb deficits or any other medical comorbidities that interfere significantly with gait or the ability to perform exercise testing on a bicycle ergometer
  • Severe left ventricular dysfunction (LVEF < 30%).
  • Contraindications to surgery.
  • Concurrent active treatment in another clinical trial

Treatment and study plan

Y incision Technique (YIT)

Procedure

A "Y"-shaped incision is made from the aortotomy, extending through the left coronary-noncoronary commissure into the aortomitral curtain. Thereafter, a Hemashield patch is sewn to the aortomitral curtain and the undermined aortic annulus, creating a larger space, and the bioprosthetic valve is placed and secured. Finally, the modified aortotomy is closed using the roof technique for better hemostasis and to enlarge the sinotubular junction and proximal ascending aorta. This technique allows the implantation of a valve up to five sizes larger than the native annulus.

Standard surgical enlargement techniques

Procedure

Traditional approaches include aortic root enlargement procedures such as the Nicks, Manougian, and Konno techniques; these procedures aim to widen the annulus and accommodate a larger prosthetic valve, thereby reducing the risk of PPM.

Primary outcomes

  1. Hierarchical composite of clinical and functional outcomes (Win Ratio)

    Time frame: At specified time points through 12 months

    A composite hierarchical endpoint analyzed using the Win Ratio methodology. Pairs of patients (one from each study arm) are compared based on a prioritized sequence of outcomes. The hierarchy is: 1. Time to all-cause mortality; 2. Incidence of stroke; 3. Incidence of myocardial infarction; 4. Frequency of total hospitalizations; 5. Presence of moderate/severe Prosthesis-Patient Mismatch (PPM); 6. Exercise-induced valve dysfunction; and 7. Improvement in functional status (defined as ≥1 NYHA class improvement). A "win" is assigned to the patient with the better outcome at each step.

    Win Ratio - The ratio of the total number of wins in the intervention group to the total number of wins in the control group.

Secondary outcomes

  1. Incidence of Major Adverse Events (MAE) through 12 months.

    Time frame: Up to 12 months.

    Number of participants experiencing intraoperative and 30-day complications, and long-term anatomical complications (including valve thrombosis or migration).

    Unit of Measure: Number of participants.

  2. Change in Hemodynamic Parameters (Mean Pressure Gradient).

    Time frame: Baseline, 3, 6, and 12 months.

    Assessment of the prosthetic valve mean pressure gradient as measured by transthoracic echocardiography.

    Unit of Measure: mmHg.

  3. Change in 6-Minute Walk Distance (6MWD).

    Time frame: Baseline and 12 months.

    Change from baseline in the distance walked during a 6-minute period. Unit of Measure: Meters.

  4. Change in Quality of Life (KCCQ-12 Score).

    Time frame: Baseline, 3, 6, and 12 months.

    Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score. Scores range from 0 to 100, where higher scores represent better health status.

    Unit of Measure: Points on a scale.

  5. Change in Peak Oxygen Consumption (Peak VO2)

    Time frame: Baseline and 12 months post-surgery.

    Peak VO2 attained during Cardiopulmonary Exercise Testing (CPET) using a standardized ramp protocol on a cycle ergometer or treadmill. Unit of Measure: mL/kg/min

  6. Incidence of Prosthetic Valve-Related Complications

    Time frame: 3, 6, and 12 months post-surgery.

    Number of participants experiencing specific valve-related adverse events, including prosthetic valve thrombosis, device migration, endocarditis, or structural valve deterioration (SVD) as defined by VARC-3 criteria.

    Unit of Measure: Number of participants

  7. Incidence of Early Postoperative Complications (30 Days)

    Time frame: Within 30 days post-surgery.

    A composite of safety events occurring within the early postoperative period, including major bleeding (BARC type 3 or 5), acute kidney injury (Stage 2 or 3), and new-onset permanent atrial fibrillation.

    Unit of Measure: Number of participants

  8. Change in Effective Orifice Area (EOA)

    Time frame: Baseline, 3, 6, and 12 months post-surgery.

    The Effective Orifice Area of the prosthetic valve calculated via the continuity equation using transthoracic echocardiography (TTE) measurements. Unit of Measure: cm^2

  9. Change in NYHA Functional Classification

    Time frame: Baseline, 3, 6, and 12 months post-surgery.

    Assessment of heart failure symptoms according to the New York Heart Association (NYHA) Functional Classification. Scores range from Class I (no symptoms) to Class IV (severe symptoms).

    Unit of Measure: NYHA Class (I, II, III, or IV)

Study contacts

Contact information is provided by the study sponsor or research team.

Nadav Willner, MD

CONTACT

[email protected]

+972-50-8845456

Sponsors and collaborators

Lead sponsor

willner nadav MD

Other

Registry information

Official study title

Comparative Analysis of Standard Surgical Techniques vs. "Y Incision" Technique for Aortic Root Enlargement in Patients With Small Aortic Annulus Undergoing Aortic Valve Replacement: A Randomized Open-Label Controlled Trial (CRYSTAL Trial - Comparative Research of Y-Incision vs. Standard Techniques for Aortic Root EnLargement)

Acronym: CRYSTAL

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 26, 2026
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.